The Use of Anthracyclines to Treat Pulmonary Hypertension

Categories: “Other Disorders“, “Respiratory Diseases

Reference #: 2010-030

OTC Contact: Ruchika Nijhara, PhD, MBA, CLP; Office: (202) 687-3721 (Directory Information | Send a Message)


Pulmonary hypertension is a devastating disease currently without cure. Constriction of the pulmonary arteries strains the right ventricle of the heart which eventually leads to heart failure. Current therapeutics such as vasodilators suppress the symptoms of pulmonary hypertension but do not target an underlying cause of disease which is the expansion of pulmonary vascular cells. This invention describes a novel use for anthracyclines such as daunorubicin to treat pulmonary hypertension. The invention also describes the use of anthracylines in combination with cardioprotectants.


A potential therapeutic for the treatment of pulmonary hypertension


Stage of Development

Daunorubicin has been demonstrated to kill pulmonary artery smooth muscle cells in vitro, and reduce vascular thickening in an animal model of pulmonary hypertension without causing a reduction in animal body weight.

Relevant Publications

Patent Status

PCT application filed in April 2011